Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML2489

Sigma-Aldrich

Tasquinimod

≥98% (HPLC)

Synonym(s):

1,2-Dihydro-4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-quinolinecarboxamide, ABR-215050, ABR-5050, N-Methyl-N-(4-trifluoromethylphenyl)-1,2-dihydro-4-hydroxy-5-methoxy-1-methyl-2-oxoquinoline-3-carboxamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C20H17F3N2O4
CAS Number:
254964-60-8
Molecular Weight:
406.36
MDL number:
MFCD18251454
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

InChI

1S/C20H17F3N2O4/c1-24(12-9-7-11(8-10-12)20(21,22)23)18(27)16-17(26)15-13(25(2)19(16)28)5-4-6-14(15)29-3/h4-10,26H,1-3H3

InChI key

ONDYALNGTUAJDX-UHFFFAOYSA-N

Biochem/physiol Actions

Tasquinimod is an antineoplastic agent with immunomodulatory, anti-angiogenic and anti-metastatic activity. It showed good results in overall survival improvement in castrate resistant prostate cancer. Its mechanism of action is not known, but may involve Protein S100-A9 also known as migration inhibitory factor-related protein 14 (MRP-14).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Andrew J Armstrong et al.
JAMA oncology, 4(7), 944-951 (2018-05-26)
Prostate cancer commonly metastasizes to bone, and bone metastases are associated with pathologic fractures, pain, and reduced survival. Bone disease is routinely visualized using the technetium Tc 99m (99mTc) bone scan; however, the standard interpretation of bone scan data relies
Yongquan Wang et al.
Journal of cancer research and clinical oncology, 144(9), 1751-1768 (2018-05-26)
Castration-resistant prostate cancer (CRPC) refers to prostate cancer that has progressed after initial androgen deprivation therapy (ADT). Over the years, treatment strategies for metastatic CRPC (mCRPC) have undergone considerable changes. We performed a network meta-analysis to assess the effectiveness and
K Fizazi et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 28(11), 2741-2746 (2017-10-24)
This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer not progressing during first-line docetaxel-based therapy. Patients were randomly assigned (1 : 1) to receive tasquinimod (0.25-1.0 mg/day orally) or
Zhenchuan Liu et al.
Clinical and translational medicine, 11(9), e545-e545 (2021-09-30)
Esophageal squamous cell carcinoma (ESCC) is a highly aggressive and treatment-resistant tumor. The biological implications and molecular mechanism of cancer stem-like cells (CSCs) in ESCC, which contribute to therapeutic resistance such as radioresistance, remain elusive. Quantitative real-time polymerase chain reaction
Mehdi Bouhaddou et al.
Cell, 182(3), 685-712 (2020-07-10)
The causative agent of the coronavirus disease 2019 (COVID-19) pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected millions and killed hundreds of thousands of people worldwide, highlighting an urgent need to develop antiviral therapies. Here we present a

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service